Important discussion points include: Medical history : Disclose any history of thyroid problems (especially MTC), MEN2, pancreatitis, gallbladder disease, kidney disease, gout, liver disease, or alcohol use Treatment goals : Clarify whether niacin therapy is necessary given current lipid management guidelines, which generally favor statins, ezetimibe, PCSK9 inhibitors, or other agents before niacin for cardiovascular risk reduction Glucose monitoring plan : Establish a clear schedule for blood glucose checks and hemoglobin A1c testing (typically every 3 months) to assess the combination's net effect on glycemic control Liver monitoring plan : Discuss the schedule for liver function tests if taking pharmacologic doses of niacin (baseline, 6-8 weeks during titration, and periodically thereafter) Pregnancy planning : If applicable, discuss contraception needs, as tirzepatide may reduce oral contraceptive effectiveness during initiation and dose escalation Symptom management : Review strategies for managing potential side effects from both medications, including the timing of niacin doses to minimize flushing and approaches to mitigate tirzepatide's gastrointestinal effects Patients should specifically ask about the expected timeline for therapeutic effects, warning signs that require immediate medical attention (severe abdominal pain, yellowing of skin/eyes, unusual fatigue, neck swelling), and whether any dose adjustments to existing diabetes medications may be necessary
Of course, taking this step requires another consultation with a physician
Molecular dynamics simulations therefore suggest a different behaviour for residue R299 ECL2 , which is stably involved in interactions with the peptide in the GLP-1-RGLP-1G s complex (Extended Data Table 1), and instead interacts with E34 ECD and other residues located at the ECL2 (E294 ECD , D293 ECD and N300 ECD ) in the GLP-1RTT-OAD2G s complex (Extended Data Table 2)
His approach, while personalized through medical supervision, follows principles applicable to anyone
